Skip to main content
SpringerLink
Log in

Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Ethnic and regional differences in the epidemiology and pathological aspects of Hodgkin’s lymphoma (HL) between Western and Asian patients may be associated with differences in clinical features and prognosis. We retrospectively analyzed the clinical and histopathological characteristics, therapeutic outcomes, and prognostic factors of 539 HL patients treated at 16 centers in Korea. We found that the incidence of histological subtypes of HL in Korea was similar to that in Western and other Asian countries. However, the incidence peaked between 16 and 30 years of age, unlike the bimodal age distribution seen in Western countries. In patients with stage I–IIA non-bulky disease, the complete response (CR) rate was similar between combined modality therapy and chemotherapy alone (93% vs. 84%, P = 0.44), and there was no difference in relapse-free survival (RFS) and overall survival (OS). Patients with stage I–II disease plus unfavorable factors and those with advanced-stage disease treated with combination chemotherapy regimens had an overall CR rate of 77%, with no difference between doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and non-ABVD regimens (77.2% vs. 76.8%, P = 0.95). Among those patients who achieved final CR, there was no significant difference in RFS or OS between those who achieved interim CR and PR. Only the presence of B symptoms was independently predictive of a shorter RFS. Age > 45 years, Eastern Cooperative Oncology Group 2–4, and B symptoms were independent risk factors for death. Although the incidence of HL was lower in Korea than in Western countries, the distribution of morphological subtypes, treatment outcomes, and patient prognosis were similar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H. SEER cancer statistics review, 1975–2007. National Cancer Institute, Bethesda

  2. Kuruvilla J (2009) Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009:497–506

    Article  Google Scholar 

  3. Canellos GP, Niedzwiecki D (2002) Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346:1417–1418

    Article  PubMed  Google Scholar 

  4. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21:607–614

    Article  PubMed  CAS  Google Scholar 

  5. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, Koch P, Hanel M, Pfreundschuh M, Wilhelm M, Trumper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Muller-Hermelink HK, Hasenclever D, Loffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548–4554

    Article  PubMed  Google Scholar 

  6. Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, Boyle P (2008) Cancer incidence in five continents. International Agency for Research on Cancer

  7. Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW (2006) Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 107:352–360

    Article  PubMed  Google Scholar 

  8. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS (2010) Cancer statistics in Korea: incidence, mortality and survival in 2006–2007. J Korean Med Sci 25:1113–1121

    Article  PubMed  Google Scholar 

  9. Mani H, Jaffe ES (2009) Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma 9:206–216

    Article  PubMed  Google Scholar 

  10. Carreon JD, Morton LM, Devesa SS, Clarke CA, Gomez SL, Glaser SL, Sakoda LC, Linet MS, Wang SS (2008) Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996–2004. Cancer Causes Control 19:1171–1181

    Article  PubMed  Google Scholar 

  11. Wu SJ, Chen CY, Su IJ, Tang JL, Chou WC, Ko BS, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Tien HF (2008) Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. J Formos Med Assoc 107:4–12

    Article  PubMed  Google Scholar 

  12. Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Suefuji N, Kikuchi M, Ohshima K (2008) Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int 58:174–182

    Article  PubMed  Google Scholar 

  13. Chen WL, Tsai WC, Chao TY, Sheu LF, Chou JM, Kao WY, Chen YC, Ho CL (2010) The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 89:553–562

    Article  PubMed  Google Scholar 

  14. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276

    Article  PubMed  CAS  Google Scholar 

  15. Yoon SO, Suh C, Lee DH, Chi HS, Park CJ, Jang SS, Shin HR, Park BH, Huh J (2010) Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 85:760–764

    Article  PubMed  Google Scholar 

  16. MacMahon B (1966) Epidemiology of Hodgkin's disease. Cancer Res 26:1189–1201

    PubMed  CAS  Google Scholar 

  17. Schnitzer B (2009) Hodgkin lymphoma. Hematol Oncol Clin North Am 23:747–768

    Article  PubMed  Google Scholar 

  18. Duhmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Ruhl U, Muller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Ruffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V (2001) Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914

    PubMed  CAS  Google Scholar 

  19. Engert A, Plutschow A, Eich H, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn K, Wilhelm M (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640–652

    Article  PubMed  CAS  Google Scholar 

  20. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357:1916–1927

    Article  PubMed  CAS  Google Scholar 

  21. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640–652

    Article  PubMed  CAS  Google Scholar 

  22. Canellos GP, Abramson JS, Fisher DC, LaCasce AS (2010) Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 28:1611–1615

    Article  PubMed  Google Scholar 

  23. Macdonald DA, Connors JM (2007) New strategies for the treatment of early stages of Hodgkin's lymphoma. Hematol Oncol Clin North Am 21:871–880

    Article  PubMed  Google Scholar 

  24. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489

    Article  PubMed  CAS  Google Scholar 

  25. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A (2010) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 95:494–500

    Article  PubMed  CAS  Google Scholar 

  26. Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B (1997) Treatment of advanced Hodgkin's disease with chemotherapy–comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:1638–1645

    PubMed  CAS  Google Scholar 

  27. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 16:19–26

    PubMed  CAS  Google Scholar 

  28. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 14:1421–1430

    PubMed  CAS  Google Scholar 

  29. Diehl V, Behringer K (2006) Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma? Cancer Invest 24:461–465

    Article  PubMed  CAS  Google Scholar 

  30. Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, Burgers JM, Thomas J, Monconduit M, Noordijk EM et al (1991) Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 114:361–365

    PubMed  CAS  Google Scholar 

  31. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630–1636

    PubMed  CAS  Google Scholar 

  32. Mauch P, Goodman R, Hellman S (1978) The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42:1039–1045

    Article  PubMed  CAS  Google Scholar 

  33. Tubiana M, Henry-Amar M, Hayat M, Burgers M, Qasim M, Somers R, Sizoo W, Van der Schueren E (1984) Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease. Cancer 54:885–894

    Article  PubMed  CAS  Google Scholar 

  34. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506–1514

    Article  PubMed  CAS  Google Scholar 

  35. Zander T, Wiedenmann S, Wolf J (2002) Prognostic factors in Hodgkin's lymphoma. Ann Oncol 13(Suppl 1):67–74

    PubMed  Google Scholar 

  36. Nogova L, Reineke T, Eich HT, Josting A, Muller-Hermelink HK, Wingbermuhle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Muller RP, Diehl V, Engert A (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683–1687

    Article  PubMed  CAS  Google Scholar 

  37. Wirth A, Yuen K, Barton M, Roos D, Gogna K, Pratt G, Macleod C, Bydder S, Morgan G, Christie D (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104:1221–1229

    Article  PubMed  Google Scholar 

  38. Maeda LS, Advani RH (2009) The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 21:397–400

    Article  PubMed  CAS  Google Scholar 

  39. Lee AI, LaCasce AS (2009) Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist 14:739–751

    Article  PubMed  Google Scholar 

  40. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Divine M, Brice P (2010) Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 116:631–639

    Article  PubMed  Google Scholar 

  41. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A (2010) Lymphocyte-predominant Hodgkin lymphoma–clinical features and treatment outcomes from a 30-year experience. Ann Oncol 21:2061–2068

    Article  PubMed  CAS  Google Scholar 

  42. Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, Bredenfeld H, Skripnitchenko R, Muller RP, Muller-Hermelink HK, Diehl V, Engert A (2008) Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434–439

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A062260).

Conflict of interest

The authors declare that there was no conflict of interest.

Author information

Authors and Affiliations

  1. Hematology–Oncology Clinic, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Republic of Korea

    Young-Woong Won & Hyeon-Seok Eom

  2. Division of Hematology–Oncology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University, Seoul, Republic of Korea

    Jung Hye Kwon

  3. Division of Hematology–Oncology, Department of Medicine, Dankook University Hospital, Dankook University, Cheonan, Republic of Korea

    Soon Il Lee

  4. Department of Internal Medicine, Dong-A University Medical Center, Dong-A University, Busan, Republic of Korea

    Sung Yong Oh

  5. Division of Hematology–Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea

    Won Seog Kim & Seok Jin Kim

  6. Division of Hematology–Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University, Seoul, Republic of Korea

    Jong-Ho Won & Kyoung Ha Kim

  7. Department of Hematology–Oncology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University, Bucheon, Republic of Korea

    Seong Kyu Park

  8. Department of Internal Medicine, Severance Hospital, Yonsei University, Seoul, Republic of Korea

    Jin Seok Kim

  9. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

    Cheolwon Suh & Dok Hyun Yoon

  10. Department of Hematology–Oncology, Ajou University Hospital, Ajou University, Suwon, Republic of Korea

    Joon Seong Park

  11. Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University, Daegu, Republic of Korea

    Min Kyoung Kim

  12. Division of Hematology–Oncology, Ulsan University Hospital, University of Ulsan, Ulsan, Republic of Korea

    Hawk Kim

  13. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

    Hye Jin Kang

  14. Division of Hematology–Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul, Republic of Korea

    Yeung-Chul Mun

  15. Division of Hematology–Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University, Jeonju, Republic of Korea

    Jae-Yong Kwak

  16. Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University, Anyang, Republic of Korea

    Hyo Jung Kim

Authors
  1. Young-Woong Won
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jung Hye Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soon Il Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sung Yong Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Won Seog Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seok Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jong-Ho Won
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kyoung Ha Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seong Kyu Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jin Seok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Cheolwon Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dok Hyun Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Joon Seong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Min Kyoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hawk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hye Jin Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yeung-Chul Mun
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Jae-Yong Kwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Hyo Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Hyeon-Seok Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyeon-Seok Eom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Won, YW., Kwon, J.H., Lee, S.I. et al. Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Ann Hematol 91, 223–233 (2012). https://doi.org/10.1007/s00277-011-1297-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-011-1297-x

Keywords

Search

Navigation